Dystrophin restoration or replacement aims to treat the underlying cause of Duchenne which is the lack of dystrophin, the protein that provides stability to the muscles. Gene editing using CRISPR/Cas9 technology is one way that dystrophin restoration is being explored. This panel will feature researchers and clinicians developing pre-clinical gene editing strategies that may be used to treat patients with Duchenne.
